Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer

Carrato, Alfredo; Rosell, Rafael; Camps, Carlos; Antón, Antonio; García-Gómez, Ramón; Aranda, Enrique; Massutí, B.; Dı́az-Fernández, N; Sánchez, José Javier; Garcia-Paredes, M. L.

doi:10.1016/s0169-5002(97)00029-9

Cited by 15 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the initial trials evaluated a weekly schedule of vinorelbine at a dose of 25 --30 mg/m 2 [16,17,[64][65][66][67][68]. A Spanish Phase II trial used a modified schedule in adult advanced NSCLC patients, by suppressing the dose corresponding to day 15, with the aim to allow bone marrow recovery and to avoid the administration of the drug at the nadir of the cycle [69]. Vinorelbine was administered at the dose of 30 mg/m 2 on days 1 and 8 every 21 days, which was equivalent to a 20 mg/m 2 /week dose intensity.…”

Section: Safety Evaluation 231 Safety In Clinical Studiesmentioning

confidence: 99%

Vinorelbine for non-small cell lung cancer

Piccirillo

Daniele

Maïo

et al. 2010

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

Section: Safety Evaluation 231 Safety In Clinical Studiesmentioning

confidence: 99%

Vinorelbine for non-small cell lung cancer

Piccirillo

Daniele

Maïo

et al. 2010

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…Furthermore, its enhanced affinity for mitotic tubules instead of axonal microtubules is likely to account for its better efficacy and improved toxicity profile over other vinca alkaloids 15. A number of Phase II trials in Advanced NSCLC have shown single‐agent response rates of 8% to 37% 16–19. A large, pivotal European Phase III trial compared single‐agent vinorelbine with vinorelbine/cisplatin as well as with the European standard of vindesine/cisplatin 20.…”

mentioning

confidence: 64%

Compatibilization by main‐chain thermotropic liquid crystalline ionomer of blends of PBT/PP

Zhang

Feng

2002

J of Applied Polymer Sci

View full text Add to dashboard Cite

ABSTRACT:The miscibility and mechanical properties of the blends of polybutylene terephthalate (PBT) and polypropylene (PP) with a liquid crystalline ionomer (LCI) containing a sulfonate group on the terminal unit as a compatibilizer were assessed. SEM and optical microscopy (POM) were used to examine the morphology of blends of PBT/PP compatibilized by LCI. DSC and TGA were used to discuss the thermal properties of PBT/PP blends with LCI and without LCI. The experimental results revealed that the LCI component affect, to a great extent, the miscibility and crystallization process and mechanical property of PBT/PP blends. The fact is that increasing LCI did improve miscibility of PBT/PP blends and the addition of 1% LCI to the PBT/PP blends increased the ultimate tensile strength and the ultimate elongation.

show abstract

“…Single-agent vinorelbine has demonstrated antitumor activity in the first-line treatment of advanced NSCLC, with overall response rates of 8%-37% [7][8][9][10]. In addition, vinorelbine in combination with cisplatin is associated with superior response and survival rates compared with cisplatin alone [11].…”

Section: Introductionmentioning

confidence: 99%

“…Gemcitabine in combination with cisplatin has been shown to be effective in the first-line treatment of patients with advanced NSCLC [2]. Finally, single-agent gemcitabine, docetaxel, and irinotecan, although associated with some antitumor activity, do not have established roles in the first-line setting [9,13]. Unfortunately, despite the generally superior toxicity profiles and promising antitumor activities of these newer agents compared with the standard platinum-based regimens, no clearly superior single-agent or combination regimen has emerged [4,6].…”

Section: Introductionmentioning

confidence: 99%

Update on the Role of Topotecan in the Treatment of Non-Small Cell Lung Cancer

Stewart

2004

The Oncologist

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is an aggressive disease that is generally resistant to chemotherapy. As a result, the prognosis for patients with NSCLC is poor. Currently, platinum-based regimens are the standard of care for patients with advanced NSCLC. However, these regimens are associated with severe and often cumulative hematologic and nonhematologic toxicities, limiting dose intensity. Therefore, novel chemotherapeutic agents and combination regimens may improve the outcome for these patients. A variety of new agents and combinations have been investigated in the treatment of NSCLC. However, to date, no clearly superior single-agent or combination regimen has emerged. Topotecan (Hycamtin; GlaxoSmithKline; Philadelphia, PA), a topoisomerase I inhibitor, is currently approved for the treatment of patients with relapsed small cell lung cancer (SCLC) and is associated with manageable, noncumulative, hematologic toxicities. In addition, topotecan demonstrates a favorable nonhematologic tolerability profile compared with agents currently used in the treatment of patients with NSCLC. The success of topotecan in patients with SCLC has made it an attractive option in the NSCLC setting. Topotecan-based combination regimens in the first-line treatment of NSCLC have demonstrated promising antitumor activities with favorable toxicity profiles. Many topotecan combination regimens have induced stable disease, a response that may offer meaningful clinical benefit in the palliative treatment of patients with advanced disease. Topotecan plus gemcitabine (Gemzar; Eli Lilly and Company; Indianapolis, IN) and single-agent topotecan may be particularly appropriate for patients in the second-line setting, in which palliation of symptoms is an important outcome of chemotherapy. Herein, the future role of topotecan in the first- and second-line treatment of NSCLC and the potential role of resistance mechanisms obtained from in vivo dose-response studies in designing future combination regimens are discussed.

show abstract

Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer

Cited by 15 publications

References 18 publications

Vinorelbine for non-small cell lung cancer

Vinorelbine for non-small cell lung cancer

Compatibilization by main‐chain thermotropic liquid crystalline ionomer of blends of PBT/PP

Update on the Role of Topotecan in the Treatment of Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About